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and Mette Deleuran2
Atopic dermatitis (AD) is a common skin disease associated with a TH2 response and increased levels of
TH2-associated cytokines and IgE. The mechanisms resulting in skewing the immune response in a TH2 direction in
AD are not fully elucidated. However, such skewing has recently been associated with IL-25 in a murine model for
allergic airway disease. The aim of this study was to investigate whether IL-25 may have a role in AD. We have
identified IL-25-producing cells within the dermis of AD patients and propose that these cells are dendritic cells
(DCs). This is supported by in vitro experiments that indicate that monocyte-derived DCs are capable of producing
IL-25. As null mutations of filaggrin are associated with the development of an impaired skin barrier in AD, we
investigated whether IL-25 affects filaggrin synthesis by keratinocytes. Using mRNA analysis, we have shown that
IL-25 stimulation does indeed decrease filaggrin synthesis in cultured keratinocytes. These results suggest that IL-25
produced by DCs could have a dual role as both an inducer of the TH2 response and as an inhibitor of filaggrin
synthesis, thereby directly affecting skin barrier function in AD patients.
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INTRODUCTION
Atopic dermatitis (AD) is a chronic, relapsing, inflammatory
skin disease estimated to affect 10–20% of children and 1–3%
of adults in the Western world (Schultz Larsen, 1996). In AD
patients, skin barrier dysfunction is often present and the
disease has been associated with mutations of FLG, the gene
encoding filaggrin (Palmer et al., 2006). AD is frequently
associated with comorbidities including asthma and allergic
rhinitis (the atopic triad) (Stone, 2003). CD4þ lymphocytes
are the predominant cells present in the AD cellular infiltrate.
This leads to recruitment of immunological cells including
other lymphocytes, mast cells and eosinophils, and the
disease is often associated with an elevated IgE response
(Flohr et al., 2004). T cell involvement is known to be
essential for chronic atopic diseases, and TH2-associated
cytokines are primarily present in the acute phase of AD,
whereas a mixed TH1/TH2 cytokine profile characterizes the
chronic phase of the disease (Hamid et al., 1994).
Interleukin-25 (also known as IL-17E), a distinct member
of the IL-17 family, is important for TH2-mediated immunity
to helminth infections in mice (Fallon et al., 2006; Owyang
et al., 2006), and participates in the initiation and prolonga-
tion of TH2-directed immune responses in murine models
(Hurst et al., 2002). The level of IL-25 mRNA synthesis
has been shown to be elevated in the lungs of asthmatic
patients and in the skin of AD patients (Wang et al., 2007).
Furthermore, IL-25 administration induces production of the
TH2-associated cytokines IL-4, IL-5, and IL-13 in addition to
eosinophilia and IgE production in a murine model of asthma
(Fort et al., 2001). TH2 cells, mast cells, and lung epithelial
cells are among the cell types producing this cytokine (Fort
et al., 2001; Ikeda et al., 2003; Angkasekwinai et al., 2007).
IL-25 shares the receptor IL-17 receptor homologue 1
(IL-17Rh1) (also called the IL-17B receptor and Evi27) with
IL-17B (Yao et al., 1997; Shi et al., 2000; Tian et al., 2000;
Lee et al., 2001), although it binds with a much higher affinity
(Hurst et al., 2002). IL-17Rh1 is abundantly expressed in the
liver and kidney and is also widely expressed in other organs
at lower levels (Lee et al., 2001). Recent research suggests
that IL-25 binds to a heterodimeric receptor complex
consisting of IL-17RA and IL-17Rh1 (Rickel et al., 2008),
with IL-17RA being ubiquitously expressed (Spriggs, 1997).
Owing to the similarities between AD and asthma,
particularly regarding the immune response, we speculated
that IL-25 might have a central role in AD. In this study we
show that this indeed seems to be the case, as IL-25-
producing cells are present in AD skin. Furthermore, we
show that dendritic cells (DCs), which are known to be
present in increased numbers in AD skin (Bieber et al., 1988),
are capable of producing IL-25. Finally, we have been able to
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show that IL-25 downregulates filaggrin synthesis in primary
keratinocyte cultures and may thereby provide a link
between skin inflammation and impaired skin barrier
function in AD.
RESULTS
Increased numbers of IL-25- and IL-17Rh1-expressing cells in
inflamed skin
To determine whether IL-25 and its receptor IL-17Rh1 are
present in the skin of AD patients, we performed immuno-
histochemistry on paraffin-embedded skin samples from
involved and uninvolved tissue from AD patients and from
apparently healthy control volunteers. We found that
keratinocytes in both involved and uninvolved skin from
AD patients produced IL-25 (Figure 1a), with staining most
pronounced in involved tissue. Large mononuclear cells in
the dermis also expressed IL-25. Corresponding results
were obtained in healthy controls, although the staining
was less intense (Figure 1b). In AD patients, IL-17Rh1 was
primarily present in cells along the basal membrane in the
involved skin (Figure 1a). A few IL-17Rh1-positive cells were
also present in uninvolved skin and in control tissue from
healthy volunteers (Figure 1a and b). In patients with contact
dermatitis and psoriasis, increased levels of IL-25 were
present in involved skin in comparison with uninvolved
tissue. Only low levels of IL-17Rh1 were present in these
samples (Figure 1c and d). Sections stained with isotype
control antibodies revealed no staining (data not shown).
Presence of IL-25 mRNA synthesis in biopsy samples from AD
patients and in primary keratinocyte cultures
Having located IL-25 in the skin of AD patients, we
performed quantitative real-time PCR (QRT-PCR) to evaluate
the presence of mRNA synthesis locally in the skin. An
elevated IL-25 mRNA level was observed in the skin of AD
patients in comparison with skin from healthy volunteers.
However, we observed only very low levels of IL-25 mRNA
close to the detection limit, suggesting that IL-25 synthesis
occurs outside the skin (data not shown). This was supported
by mRNA analysis of primary keratinocyte cultures from
healthy donors in which we were unable to detect IL-25
mRNA synthesis (data not shown).
Coexpression of HLA-DR and IL-25 in large mononuclear cells
in the dermis of AD skin
As large mononuclear cells along the basal membrane of AD
skin expressed IL-25 and IL-17Rh1, and as DCs are present in
increased numbers in the skin of AD patients, we decided to
investigate whether DCs are able to express IL-25. Using
confocal microscopy, we found HLA-DRþ cells expressing
IL-25, suggesting that DCs in the dermis produce IL-25 in
both involved and uninvolved AD skin (Figure 2).
Evaluation of IL-25 and IL-17Rh1 expression by DCs using flow
cytometry
To evaluate further the expression of IL-25 and its receptor on
DCs, we examined monocyte-derived DCs (MoDCs) from
healthy controls. We found that the cultured cells had a
morphology resembling DCs. In addition, the MoDCs were
examined for the presence of selected surface markers by
flow cytometry. The cells phenotypically matched DCs by
being CD3, CD14, and HLA-DRþ with a purity between
94.3 and 99.6%. Furthermore, in response to lipopolysac-
charide (LPS) stimulation, the activation markers CD80,
CD83, and CD86 were upregulated, which is in agreement
with a DC phenotype.
To determine whether DCs produce IL-25 or IL-17Rh1, we
performed flow cytometry (Figure 3). In unstimulated control
MoDCs (n¼ 8), 31% (18%, 49%) (median with interquartile
range in parenthesis) of cells expressed IL-25, whereas the
receptor IL-17Rh1 was present in 3% (1%, 8%) of cells. The
majority of IL-17Rh1-positive cells coexpressed IL-25 (76%
(71%, 88%)).
As secondary infections are common in AD skin, we
investigated the effect of LPS stimulation on the number of IL-
25-producing cells. Following LPS stimulation (n¼8), the
number of IL-25-expressing DCs increased by 10% (1%,
12%) (P¼ 0.05). The number of IL-17Rh1-positive cells was
not affected by LPS stimulation. In addition, we examined the
effect of thymic stromal lymphopoietin (TSLP) stimulation on
the expression of IL-25 and IL-17Rh1, as this chemokine has
previously been shown to be increased in AD skin (Soumelis
et al., 2002). However, TSLP stimulation (n¼3) did not affect
the numbers of IL-25- or IL-17Rh1-expressing cells signifi-
cantly.
IL-25 protein expression in MoDCs
As the number of IL-25-producing cells increased in response
to LPS, and was unaffected by TSLP stimulation, we have
looked for evidence of the presence on IL-25 protein in
stimulated MoDCs using western blot analysis. An equal
amount of protein was loaded in each lane. LPS stimulation
resulted in a reduced proportion of IL-25 protein relative to
total cellular protein, whereas the level was unchanged or
slightly decreased in response to TSLP (Figure 3). Thus, these
results confirm the specificity of the antibody clone that we
have used for both immunohistochemistry and flow cytometry.
Filaggrin synthesis is reduced by IL-25 stimulation in primary
keratinocyte cultures
Although DCs are present in increased numbers in the skin,
the most abundant cell type in the epidermis is the
keratinocyte. In recent years, much focus has been directed
at keratinocytes to explain the cause of AD. In particular,
mutations within the FLG have been associated with the
impaired skin barrier function observed in AD patients
(Palmer et al., 2006). To investigate whether IL-25 affects
filaggrin synthesis in AD skin, we stimulated primary
keratinocyte cultures from healthy patients (n¼ 5) with
recombinant human IL-25. This resulted in a decrease in
the level of filaggrin mRNA in all patients. Following
stimulation with 10 ngml1 of IL-25, the average level of
filaggrin mRNA decreased between 21 and 73%, whereas
stimulation with 20 ngml1 resulted in a statistically sig-
nificant decrease between 23 and 92% compared with the
unstimulated sample (Po0.01) (Figure 4).
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These results suggest that IL-25 could have a role in AD
not only by stimulating the TH2 differentiation as described
by others (Hurst et al., 2002; Fallon et al., 2006; Owyang
et al., 2006) but also by downregulating filaggrin synthesis in
the skin and thereby providing a link between the inflamma-
tory reaction and impaired skin barrier function.
DISCUSSION
In this study, we suggest that IL-25 is a possible mediator in
AD and propose that DCs are an important source of the
cytokine. Our hypothesis is supported by the identification of
HLA-DRþ cells within the dermis expressing IL-25, along
with the fact that in vitro-cultured DCs produce IL-25.
DCs are essential in the priming of CD4þ TH cells in the
lymph nodes, and are considered important in their
differentiation (Eisenbarth et al., 2003). Furthermore, several
studies have identified DCs as important factors in the
induction of TH2-mediated immune responses (Lambrecht
et al., 2000; Soumelis et al., 2002). These results further
indicate that DCs could have a role in the initiation of a TH2
response in AD skin. Concomitant with these results, it has
been shown that TSLP-stimulated DCs induce the expression
of IL-17Rh1 by TH2 cells (Wang et al., 2007), thus supporting
the existence of a DC/IL-25 axis.
We found that approximately 30% MoDCs produce IL-25
and we hypothesize that the ability of DCs to modulate the
immune response in a TH2 direction can be mediated by
IL-25. LPS activation resulted in an increased number of
IL-25-producing cells, as determined by flow cytometry,
although western blotting revealed a decrease in the ratio of
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Figure 1. Presence of IL-25 and IL-17Rh1 in skin sections. Skin biopsies from involved (Inv.) and uninvolved (Uninv.) atopic dermatitis, psoriasis, and contact
dermatitis tissues and from healthy volunteers (Control) were evaluated for the presence of IL-25 and its receptor IL-17Rh1. (a) IL-25-producing cells were
present in both involved and uninvolved AD skin. Staining was most pronounced in involved skin. Large mononuclear cells also expressed IL-25. IL-17Rh1
was predominantly present along the basal membrane of involved skin. (b) In healthy volunteers, IL-25 staining was located in the epidermis and only few
IL-17Rh1 cells were present. (c, d) In skin sections from patients with allergic contact dermatitis or psoriasis, IL-25 expression was present in low levels in
inflamed skin. Only very few cells expressed IL-17Rh1. Bar¼ 50 mm. IL-17Rh1, IL-17 receptor homologue 1.
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IL-25 protein in relation to the overall protein production by
the cells. Escherichia coli LPS has previously been shown to
induce IL-12(p70) production in DCs through a TLR4-
dependent mechanism, leading to a skewing of the immune
response in a TH1 direction (Pulendran, 2004); thus, a
reduction in the amount of TH2 inducing IL-25 is in
concordance with these results.
In contrast to the results obtained by Wang et al. (2007),
we could only detect very low levels of IL-25 mRNA,
suggesting that IL-25 synthesis primarily occurs outside the
skin. Similarly, in primary keratinocyte cultures, we were
unable to detect mRNA synthesis, which further supports
these results. IL-25-producing DCs, which migrate into the
skin, can explain these observations. In general, DCs, which
are present in elevated numbers within the skin of AD
patients, migrate into their target organs (i.e., skin or lungs) in
response to a number of factors including GM-CSF and
microbial products such as LPS (Schon-Hegrad et al., 1991;
Kaplan et al., 1992). Another explanation of the lack of IL-25
mRNA detection could be that mRNA synthesis in keratino-
cytes is very low, as previously noted for other inflammatory
cytokines (Kristensen et al., 1991).
Although DCs are present in the skin, the most common
cell type in the epidermis is the keratinocyte. Consequently,
in recent years much focus has been directed at keratinocytes
to explain the cause of AD. In particular, null mutations of the
FLG have been strongly associated with the impaired skin
barrier function observed in AD patients. To study the effect
of IL-25 in AD skin, we therefore evaluated whether IL-25
could be involved in the regulation of filaggrin synthesis by
keratinocytes. We stimulated primary keratinocytes with
IL-25 and subsequently measured the mRNA level of filaggrin.
We found that IL-25 stimulation reduces filaggrin synthesis in a
dose-dependent manner, suggesting that IL-25 can affect skin
barrier function independently of mutations of FLG and thus
may provide a mechanism by which an inflammatory immune
response can directly affect skin barrier function.
We propose a role for IL-25 in AD in which IL-25
produced by, e.g., DCs and mast cells binds to receptors
present on keratinocytes and thereby leads to a down-
regulation of filaggrin in the skin. This could directly result in
impaired skin barrier function. Furthermore, it has previously
been determined that IL-25 can function directly or indirectly
on TH2 cells, leading to the production of TH2-associated
cytokines IL-4, IL-5, and IL-13 in addition to increased IgE
levels and eosinophilia.
Thus, taken together, these results suggest that DCs, which
are present in skin in increased numbers, may have a pivotal
role in AD by the production of IL-25. Not only can IL-25-
producing DCs skew the immune response in a TH2 direction,
IL-25-producing DCs may also be important in the develop-
ment of the impaired skin barrier observed in AD patients.
MATERIALS AND METHODS
Collection of skin biopsy samples
Punch biopsies (5mm) from involved and uninvolved skin from adult
patients and from the healthy skin of healthy control volunteers were
collected after obtaining written consent in accordance with the
guidelines of the Central Denmark Regional Committee on
Biomedical Research Ethics and the Declaration of Helsinki
Principles. No patients were receiving systemic steroid treatment at
the time of the study.
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Figure 2. Coexpression of HLA-DR and IL-25 in the dermis. In both uninvolved and involved tissues, large mononuclear cells coexpressing HLA-DR
(green) and IL-25 (red) were present, suggesting that dendritic cells of the dermis produce IL-25. Nuclei were visualized by 46-diamidino-2-phenyl indole
(DAPI, blue). Bar¼20 mm.
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Immunohistochemistry
Formaldehyde-fixed, paraffin-embedded skin sections were placed
on superfrostþ slides, deparaffinized in xylene and rehydrated in an
ethanol gradient. The antigen was demasked by boiling for
20minutes in Tris-buffer (pH 6.0). Thereafter, the tissue was blocked
for endogenous avidin and biotin (DakoCytomation, Glostrup,
Denmark), and for nonspecific background staining using 10%
normal goat serum (DakoCytomation). The slides were incubated
overnight with 1mgml1 of primary mouse antihuman IL-25
antibody (clone 182203; R&D Systems, Minneapolis, MN) or mouse
antihuman IL-17Rh1 antibody (clone 170220; R&D Systems) or
appropriate isotype controls in identical concentrations (clone
X0931, DakoCytomation; 27-35, BD Pharmingen, Franklin Lakes,
NJ), followed by incubation for 30minutes with the biotin-
conjugated donkey anti-mouse antibody diluted 1:800 (715-066-
150; Jackson ImmunoResearch, West Grove, PA). Bound antibody
was detected using alkaline phosphatase-conjugated streptavidin
(Sigma-Aldrich, St Louis, MO) diluted 1:250 for 30minutes. Positive
staining was visualized using the Fuchsine Substrate Chromogen
System (DakoCytomation) for 6minutes in accordance with the
manufacturer’s descriptions. After each incubation step, the slides
were washed in TBS. The tissue was counterstained using Mayer’s
hematoxylin.
Confocal microscopy
Cryopreserved skin biopsy specimens from AD patients were
acetone fixed, blocked for endogenous avidin and biotin and for
nonspecific background staining using 10% normal goat serum as
described above. The sections were stained using mouse antihuman
HLA-DR (clone CR3-43; Dako) and biotinylated goat antihuman
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Figure 3. IL-25 and IL-17Rh1 production by MoDCs. (a) Gating strategy for DCs. DCs were selected on the forward/side scatter plot. (b) Dot plot of a
representative unstimulated DC culture. Approximately 30% of MoDCs produce IL-25 and o3% express IL-17Rh1. The majority of IL-17Rh1þ cells
coexpressed IL-25. (c, d) Scatter dot plot with median and interquartile range depicting the percentage of IL-25þ and IL-17Rh1þ MoDCs. LPS stimulation
resulted in an increased number of IL-25þ cells (P¼ 0.05), whereas no effect was observed following TSLP stimulation. IL-17Rh1 expression was unchanged by
both stimulations. (e) Western blot analysis of the IL-25 protein level in MoDCs. LPS and TSLP stimulations both resulted in reduced IL-25 protein level in
the samples. b-Actin was included as a loading control. Results are representative of three experiments. IL-17Rh1, IL-17 receptor homologue 1; LPS,
lipopolysaccharide; TSLP, lyphopoietin; Unstim., unstimulated.
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IL-25 (BAF1258; R&D Systems, Dako, Glostrup, Denmark). The
primary antibodies were detected by FITC-conjugated goat anti-
mouse secondary antibody and Alexa 547-conjugated streptavidin
(Invitrogen, Carlsbad, CA). Nuclei were visualized by DAPI. Images
of representative fields were acquired using the 488 nm line of a
multiline argon laser, the 543 nm line of the green helium–neon
laser, and the 633 nm line of the helium–neon laser on a confocal
laser scanning microscope (LSM710; Zeiss, Jena, Germany) with a
 63 oil-immersion objective.
Isolation of RNA from skin biopsy specimens
For IL-25 mRNA analysis, punch biopsy specimens from AD patients
were transferred to 1ml of 80 1C cold RNAlater-ICE (Ambion,
Austin, TX) and stored at 80 1C until further use. The samples
were transferred to 175ml of SV RNA Lysis Bufferþ b-mercaptoetha-
nol (SV Total RNA Isolation System; Promega, Madison, WI) and
homogenized. RNA purification, including DNase treatment of the
samples, was carried out in accordance with the manufacturer’s
descriptions (Promega).
Culture of primary keratinocytes
Normal human keratinocytes were collected and cultured as
previously described by others (Kragballe et al., 1985l Soegaard-
Madsen et al., 2010).
Stimulation of normal human keratinocytes
For the analysis of IL-25 synthesis, primary keratinocytes were grown
to 50–60% confluency and stimulated with 10 ngml1 of IL-1b
(200-1B; PeproTech, Rocky Hill, NJ) for 24 and 48 hours. For
QRT-PCR analysis, cells were washed twice in ice-cold phosphate-
buffered saline (PBS) and total RNA was isolated using the SV Total
RNA Isolation System (Promega) as previously described (Johansen
et al., 2007). All stimulations were performed in duplicate.
For the analysis of filaggrin mRNA level, cells were stimulated
at 70–80% confluency with carrier-free recombinant human IL-25
(10 and 20 ngml1) (1258-IL; R&D Systems) for 5 days. On day 3,
the medium supplemented with IL-25 was changed. The cells were
collected on day 5 and total RNA was isolated as described above.
All QRT-PCR analyses were performed in triplicate.
Generation of dendritic cells
Peripheral blood mononuclear cells were collected from buffy coats
from healthy blood donors (Skejby Hospital, Denmark) according to
protocols approved by the local ethics committee. CD14þ monocytes
were isolated using a Dynabeads Untouched Human Monocytes
isolation kit (Invitrogen) in accordance with the manufacturer’s
recommendations with the exception that buffers contained human
serum albumin instead of BSA. Monocytes were suspended in
culture medium (sterile filtered RPMI 1640 supplemented with 2%
human AB serum, 2mM glutamine, and 20mgml1 gentamicin).
To initiate the differentiation of monocytes into DCs, we added
20 ngml1 of recombinant human IL-4 (PeproTech) and 100 ngml1
of recombinant human GM-CSF (Leukomax; Schering-Plough,
Kenilworth, NJ) to the medium and 10ml cell suspension was
added to 10 cm Nunclon surface Petri dishes (Nunc, Roskilde,
Denmark). Culture medium (3ml) supplemented with 300 ngml1
GM-CSF and 20 ngml1 IL-4 was added to the cells on day 3 and
10ml medium containing 200 ngml1 GM-CSF and 40ngml1 IL-4
was added on day 5. On day 6, the cells were either stimulated with
10 ngml15 E coli LPS (L2654; Sigma-Aldrich), 10 ngml1 recombi-
nant human TSLP (R&D systems), or left untreated for 24 hours.
Brefeldin A (Sigma-Aldrich) (0.2% of the total volume of medium)
was added 4hours before collection. The cells were collected by
flushing with cold RPMI.
Flow cytometry
The expression of a number of cell markers was used to
evaluate monocyte differentiation into DCs in eight healthy
blood donors. Antibodies directed against the following cell
markers were included in addition to the appropriate isotype
controls: HLA-DR, CD3, CD11, CD14, CD19, CD40, CD80,
CD83, and CD86. The expression of the antibodies was
evaluated by flow cytometry. The cells were adjusted to 0.3 106
cells per ml in PBS/0.5% BSA/0.09% NaN3 (PBS/BSA/Az) and the
antibodies and isotype controls were added as described in Table 1.
The cells were incubated for 45minutes at room temperature, and
washed twice with PBS/BSA/Az. Samples were fixed in 0.9% (v/v)
formaldehyde.
For the evaluation of IL-25 and IL-17Rh1 expression, we adjusted
cells to 0.3 106 cells per ml in PBS/BSA/Az, and 10 ml FITC-
conjugated IL-17Rh1 (clone 170220; R&D Systems) and 20 ml
viability marker Via-Probe/7AAD (BD Biosciences, San Jose, CA)
were added. The samples were incubated for 30minutes at 5 1C
and washed twice in PBS/BSA/Az. Thereafter, the cells were
permeabilized using 0.5ml 1 FACS permeabilizing solution 2
(BD Biosciences). Subsequently, the samples were stained with anti-
IL-25 PE (clone 182203; R&D Systems) for 30minutes at 4 1C,
washed, and fixed in 0.9% (v/v) formaldehyde.
All samples were analyzed using an FC500 Flow Cytometer
(Beckman Coulter, Miami, FL). FlowJo software version 8.7.3 (Tree
Star, Ashland, OR) was used for data analysis. DCs were selected
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Figure 4. IL-25 stimulation results in reduced filaggrin synthesis. Filaggrin
mRNA synthesis of primary keratinocyte cultures from five healthy volunteers
was evaluated following stimulation with 10 and 20 ngml1 of recombinant
human IL-25 using QRT-PCR. The plot represents mean and standard
error of mean (SEM) of IL-25 levels in duplicate experiments on each donor.
The filaggrin mRNA level was reduced in a dose-dependent matter in
response to IL-25, indicating that IL-25 could have a role in atopic dermatitis
by directly interfering with the skin barrier function (**Po0.01).
stim., stimulation; unstim., unstimulated sample.
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using the forward/side scatter and purity was characterized in
accordance with the above-mentioned cell markers.
Western blotting
Western blot analysis of DCs was performed as previously described
(Holm et al., 2009) and the following antibodies were used for the
evaluation of protein expression by the cells: unconjugated mouse
antihuman IL-25 (clone 182203; R&D Systems) and horseradish
peroxidase-conjugated mouse antihuman b-actin (Clone c4; Santa
Cruz Biotechnology, Santa Cruz, CA). Unconjugated antibodies
were visualized using horseradish peroxidase-conjugated donkey
antimouse antibody (715-036-150; Jackson ImmunoResearch).
Quantitative real-time PCR analysis of filaggrin synthesis in
keratinocytes
Skin biopsy samples and human keratinocyte cell cultures were
examined using RT–PCR. The skin biopsies were examined for the
presence of IL-25 mRNA, whereas the cell cultures were examined
for filaggrin mRNA. For both setups, RPLP0 (eukaryotic 18S rRNA)
was used as the housekeeping gene. cDNA synthesis was performed
using TaqMan Reverse Transcription reagents (Applied Biosystems,
Foster City, CA). Primers and probes for IL-25, filaggrin, and
RPLP0 were predesigned and purchased from Applied Biosystems
(TaqMan 20 Assays-On-Demand Expression Mix, assay IDs
Hs00224471.m1, Hs00856927.g1, and Hs99999902.m1). The
probes were FAM-labeled MGB probes with a nonfluorescent
quencher. QRT-PCR was performed using TaqMan 2 Universal
PCR Master Mix No AmpErase (Applied Biosystems). Each gene was
run in triplicate on a RotorGene 3000 real-time PCR platform
(Corbett Research, Sydney, Australia). Relative gene expression
levels were determined using the relative standard curve method as
outlined in User Bulletin no. 2 (ABI Prism 7700 Sequencing
Detection System; Applied Biosystems).
Statistical analysis
For the evaluation of filaggrin mRNA synthesis from triplicate
analyses in five donors, we analyzed data by one-way analysis of
variance (Friedman’s test) with post hoc comparison by Dunn’s
multiple comparison test. When analyzing the flow cytometry results
of the numbers of IL-25- and IL-17RB-positive cells, Wilcoxon’s
signed-rank test was applied. A P-valueo0.05 was considered to be
statistically significant.
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